’ spread margin with the reliability of production unit. Financial Ratios Q3 2017 Q3 2016 Gross profit margin 17.7% 10.1% Net profit margin 7.4% 2.6% Debt to Equity ratio 0.12 0.14 Earnings per share 0.30
% 11.9% Debt to Equity ratio 0.09 0.14 Earnings per share 0.90 0.53 ROA 19.6% 12.9% ROE 21.4% 13.5% Gross profit margin = Gross Profit (Total Sales – Costs of Sales) to Sales Net profit margin = Net Profit
margin 25.3% 18.1% Net profit margin 17.6% 11.9% Debt to Equity ratio 0.17 0.10 Earnings per share 0.66 0.46 ROA 13.1% 11.0% ROE 14.0% 10.9% Gross profit margin = Gross Profit (Total Sales – Costs of Sales
148.64 154.11 148.23 5.88 3.97 Profit before share loss from investment in joint venture and income tax 19.89 21.82 17.21 22.22 (5.01) (22.55) Share of loss from investment in joint venture (1.00) (0.86
5.52 14.57 Profit before share loss from investment in joint venture and income tax 2.90 2.83 2.87 2.60 0.27 10.54 Share of loss from investment in joint venture - (1.53) - - - - Profit before income tax
profit 127,606 44,483 83,123 186.86 Net porofit margin (%) 7.01 3.50 3.52 100.65 Net profit per share (Baht) 0.13 0.04 0.08 Unit : THB'000 2019 2018 The main businesses of the Company and its subsidiaries
2,666.53 Gross profit 1,437.43 801.69 Gross profit margin 31.18% 23.11% 6. In the year of 2019, details of share of profit from investment in associates compared to the year of 2018 are as follows: Name of
amounted to Baht 70. 00 million with net share premium of Baht 503. 33 million. • Total comprehensive income for 9 months Baht 43.42 million. • Dividend paid Baht 16.80 million. P a g e 3 | 8 The analysis of
115.40% Gross profit margin 61.51% 59.98% 1.53% Net profit margin 45.50% 36.59% 8.91% บริษัท ดโีอด ีไบโอเทค จ ำกดั (มหำชน) 111 หมู่ที่ 2 ต ำบลท่ำจีน อ ำเภอเมืองสมุทรสำคร จังหวดัสมุทรสำคร 74000 111 Moo 2
(0.07) (0.01) (0,06) 1032.86 (0.07) (0.01) (0.06) 1032.86 Total Expenses (34.e2) (34.41) (0.51) 1.49 (35.08) (34.46) (0.62) 1.79 Profit before share loss ftom investrnent in joint venture and inclme tax